DrugPatentWatch Database Preview
Drugs in Development Information for TA-8995
» See Plans and Pricing
What is the drug development status for TA-8995?
TA-8995 is an investigational drug.
There have been 8 clinical trials for TA-8995.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Dyslipidemias and [disabled in preview]. The leading clinical trial sponsors are Xention Ltd, Mitsubishi Tanabe Pharma Corporation, and [disabled in preview].
There is one US patent protecting this investigational drug and eleven international patents.
Summary for TA-8995
| US Patents | 1 |
| International Patents | 11 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 16 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-08-01) |
| Vendors | 4 |
Recent Clinical Trials for TA-8995
| Title | Sponsor | Phase |
|---|---|---|
| Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 | Xention Ltd | Phase 1 |
| ADME Study in Healthy Male Subjects With TA-8995 | Xention Ltd | Phase 1 |
| A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a) | Xention Ltd | Phase 1/Phase 2 |
Clinical Trial Summary for TA-8995
Top disease conditions for TA-8995
Top clinical trial sponsors for TA-8995
US Patents for TA-8995
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TA-8995 | Start Trial | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors | DEZIMA PHARMA B.V. (NL) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TA-8995
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TA-8995 | Argentina | 101724 | 2034-08-28 | Start Trial |
| TA-8995 | Australia | 2015307306 | 2034-08-28 | Start Trial |
| TA-8995 | Canada | 2959488 | 2034-08-28 | Start Trial |
| TA-8995 | China | 107072999 | 2034-08-28 | Start Trial |
| TA-8995 | European Patent Office | 3185869 | 2034-08-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
